The growth of Viagra and its influence on the pharmaceutical landscape presents a complicated question for shareholders. While the initial sales figures were remarkable, the exclusivity has expired, leading to a flood of copycat alternatives that are eroding revenue. In addition, the market is facing difficulties related to demographic trends an… Read More